Search

Search bills, members, committees and pages...

Sign In

H.R. 1414

U.S. House•In House Committee

Summary

H.R. 1414, “Cameron’s Law”, was introduced in the House on Feb 18, 2025 by Rep. Josh Gottheimer (D) with 19 co-sponsors. It was referred to Ways And Means, and last saw action on Feb 18, 2025: Referred to the House Committee on Ways and Means.

Record

Text

H.R. 1414 has 19 co-sponsors.

hb1414/introduced-in-house.txt
119 HR 1414 IH: Cameron’s Law
 U.S. House of Representatives
 2025-02-18
 text/xml
 EN
 Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
 I  119th CONGRESS  1st Session  H. R. 1414  IN THE HOUSE OF REPRESENTATIVES   February 18, 2025   Mr. Gottheimer  (for himself,  Mr. Bacon ,  Mr. Panetta , and  Mr. Suozzi ) introduced the following bill; which was referred to the  Committee on Ways and Means    A BILL
To amend the Internal Revenue Code of 1986 to restore the amount of the orphan drug tax credit.
1.
Short title
This Act may be cited as   Cameron’s Law  .
2.
Restoration of amount of orphan drug tax credit
(a)
In general
 Section 45C(a)  of the Internal Revenue Code of 1986 is amended by striking  25 percent  and inserting  50 percent .
(b)
Effective date
The amendment made by this section shall apply to taxable years beginning after the date of the enactment of this Act.

Tracker

The tracker indicates the progress of this legislation as it moves through the legislative process.

  1. Introduced2025-02-18
  2. Passed House
  3. Passed Senate
  4. Conference
  5. To President
  6. Became Law

CRS Summary

The summaries are the Congressional Research Service’s, one per stage. Read them in full.

Introduced in House Feb 18, 2025

hb1414/introduced-in-house.md

Shown Here:
Introduced in House (02/18/2025)

Cameron's Law

This bill increases the orphan drug tax credit to 50% (from 25%) of qualified clinical testing expenses paid or incurred in the development of drugs to treat certain rare diseases or conditions.

As background, the Tax Cuts and Jobs Act reduced the orphan drug tax credit (for tax years after 2017) to 25% of qualified clinical testing expenses (e.g., wages, supplies, and certain contract expenses) paid or incurred in the development of drugs to treat certain rare diseases or conditions. For 2017 and prior tax years, the orphan tax credit was 50% of such expenses paid or incurred.

Sponsors

Rep. Josh Gottheimer (D) sponsors H.R. 1414, and 19 members have co-sponsored it, 3 of them from the day it was introduced.

Committees

H.R. 1414 went before 1 committee: Ways and Means.

Ways and Means
Ways and Means
Referred To · Feb 18, 2025 · 1,160 Bills

Actions

H.R. 1414 has taken 2 actions since Feb 18, 2025.

ChamberAction
Feb 18, 2025
House
Introduced in House
Feb 18, 2025
House
Referred to the House Committee on Ways and Means.Ways and Means Committee

Votes

H.R. 1414 has not gone to a roll call.

Titles

H.R. 1414 goes by 3 titles, 1 of them short titles.

  • Cameron’s Law — Display Title
  • Cameron’s Law — Short Title(s) as Introduced
  • To amend the Internal Revenue Code of 1986 to restore the amount of the orphan drug tax credit. — Official Title as Introduced

Lobbying

18 clients hired 18 firms and 58 registered lobbyists who named H.R. 1414 in 85 quarterly filings, 2025 to 2026. Reported under the Lobbying Disclosure Act; a filing’s income covers everything its registrant worked that quarter, so the amounts below are the filings’, not this bill’s.

Filed under Health Issues, Medicare/Medicaid, Taxation/Internal Revenue Code, Pharmacy, Medical/Disease Research/Clinical Labs, Trade (domestic/foreign), Copyright/Patent/Trademark, Budget/Appropriations.

Clients

Who paid to be heard, by how many filings named the bill.

ClientBusinessStateFirmsFilingsReported
TRAVERE THERAPEUTICSPrescription pharmaceutical manufacturer of medications.California213$480K
SOLENO THERAPEUTICS, INC.Soleno is focused on development of novel therapeutics for treatment of rare diseases.California28$220K
ACADIA PHARMACEUTICALS—California16—
ASTRAZENECA PHARMACEUTICALS LP—Delaware16—
HEALTHCARE INSTITUTE OF NEW JERSEY—New Jersey16—
IONIS PHARMACEUTICALS, INC.Biotechnology company.California16—
PTC THERAPEUTICS, INC.—New Jersey16—
VERTEX PHARMACEUTICALS INCORPORATED—Massachusetts16—
ASTRIA THERAPEUTICS, INC.Develop therapies for patients with HAE, rare, and niche allergic and immunologic diseasesMassachusetts14$160K
ALKERMES, INC.—Massachusetts14—
RARE DISEASE COMPANY COALITIONHealthcareDistrict of Columbia14—
MODERNATX, INC.Pharmaceutical and biotechnology company.Massachusetts13$90K
BRIDGEBIO PHARMA, INC.Biotech companyCalifornia13—
NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD)—District of Columbia13—
BLACK WOMEN'S HEALTH IMPERATIVENonprofit organizationGeorgia12$40K
INOZYME PHARMATreatments for PPi-Adenosine Pathway, ENPP1 Deficiency, ABCC6 Deficiency, & calciphylaxis.Massachusetts12$20K
HARMONY BIOSCIENCESpharmaceuticalsPennsylvania12—
EVERYLIFE FOUNDATION FOR RARE DISEASES—District of Columbia11—

Firms

Registrants who filed on the bill, by filings.

RegistrantClientsFilingsReported
THE KPM GROUP DC LLC311$400K
ALSTON & BIRD LLP17$480K
ACADIA PHARMACEUTICALS16—
ASTRAZENECA PHARMACEUTICALS LP16—
HEALTHCARE INSTITUTE OF NEW JERSEY16—
IONIS PHARMACEUTICALS, INC.16—
PTC THERAPEUTICS, INC.16—
TRAVERE THERAPEUTICS16—
VERTEX PHARMACEUTICALS INCORPORATED16—
ALKERMES, INC.14—
RARE DISEASE COMPANY COALITION14—
BRIDGEBIO PHARMA, INC.13—
NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)13—
SOLENO THERAPEUTICS, INC.13—
THE WASHINGTON TAX & PUBLIC POLICY GROUP13$90K
HARMONY BIOSCIENCES12—
HOLLAND & KNIGHT LLP12$40K
EVERYLIFE FOUNDATION FOR RARE DISEASES11—

Lobbyists

Named on the filings that cite the bill. The 20 named most often, of 58.

LobbyistFirmsClientsFilings
PAULA GUTIERREZ1311
ALEXANDER ROOT138
JAMES PALUSKIEWICZ117
MARK RAYDER117
ROBERT SIGGINS117
CAROLINE QUAT116
CHRISTOPHER PORTER116
HANNAH CORNWELL116
JONATHAN MCPHERSON116
JORDAN CHAPMAN116
KATIE JONES116
LISA LANGENDERFER116
MATTHEW SCHUMAKER116
MICHAEL MATTOON116
NICHOLAS BRAUGHTON116
PATROSKI LAWSON126
ROSE GALLAGHER116
SARAH ARBES116
STEVE ISSENMAN116
SWARNA VALLURUPALLI116

Filings

The documents themselves, on the Senate’s Lobbying Disclosure site, largest reported first.

ClientRegistrantPeriodReportedDocument
ASTRAZENECA PHARMACEUTICALS LPASTRAZENECA PHARMACEUTICALS LP2026 first_quarter$2.3M1st Quarter - Report
ASTRAZENECA PHARMACEUTICALS LPASTRAZENECA PHARMACEUTICALS LP2025 second_quarter$1.8M2nd Quarter - Report
ASTRAZENECA PHARMACEUTICALS LPASTRAZENECA PHARMACEUTICALS LP2026 second_quarter$1.7M2nd Quarter - Report
ALKERMES, INC.ALKERMES, INC.2025 first_quarter$1.4M1st Quarter - Report
ASTRAZENECA PHARMACEUTICALS LPASTRAZENECA PHARMACEUTICALS LP2025 third_quarter$1.4M3rd Quarter - Report
ASTRAZENECA PHARMACEUTICALS LPASTRAZENECA PHARMACEUTICALS LP2025 first_quarter$1.2M1st Quarter - Report
VERTEX PHARMACEUTICALS INCORPORATEDVERTEX PHARMACEUTICALS INCORPORATED2026 second_quarter$1.2M2nd Quarter - Report
VERTEX PHARMACEUTICALS INCORPORATEDVERTEX PHARMACEUTICALS INCORPORATED2026 first_quarter$1.1M1st Quarter - Report
VERTEX PHARMACEUTICALS INCORPORATEDVERTEX PHARMACEUTICALS INCORPORATED2025 second_quarter$1.1M2nd Quarter - Amendme…
VERTEX PHARMACEUTICALS INCORPORATEDVERTEX PHARMACEUTICALS INCORPORATED2025 second_quarter$1.1M2nd Quarter - Report
VERTEX PHARMACEUTICALS INCORPORATEDVERTEX PHARMACEUTICALS INCORPORATED2025 fourth_quarter$1.1M4th Quarter - Report
VERTEX PHARMACEUTICALS INCORPORATEDVERTEX PHARMACEUTICALS INCORPORATED2025 third_quarter$1.1M3rd Quarter - Report
ALKERMES, INC.ALKERMES, INC.2025 fourth_quarter$870K4th Quarter - Report
ALKERMES, INC.ALKERMES, INC.2025 third_quarter$840K3rd Quarter - Report
ALKERMES, INC.ALKERMES, INC.2025 second_quarter$830K2nd Quarter - Report
ACADIA PHARMACEUTICALSACADIA PHARMACEUTICALS2025 third_quarter$750K3rd Quarter - Report
ACADIA PHARMACEUTICALSACADIA PHARMACEUTICALS2026 second_quarter$700K2nd Quarter - Report
ASTRAZENECA PHARMACEUTICALS LPASTRAZENECA PHARMACEUTICALS LP2025 fourth_quarter$670K4th Quarter - Report
ACADIA PHARMACEUTICALSACADIA PHARMACEUTICALS2026 first_quarter$600K1st Quarter - Report
ACADIA PHARMACEUTICALSACADIA PHARMACEUTICALS2025 fourth_quarter$590K4th Quarter - Report

Classification

The Congressional Research Service files H.R. 1414 under Taxation, one of its 31 policy areas.

CRS Subjects

CRS assigns every bill one policy area from its 31; H.R. 1414’s is Taxation.

hr1414/policy-areas.txt
TaxationAgriculture and FoodAnimalsArmed Forces and National SecurityArts, Culture, ReligionCivil Rights and Liberties, Minority IssuesCommerceCongressCrime and Law EnforcementEconomics and Public FinanceEducationEmergency ManagementEnergyEnvironmental ProtectionFamiliesFinance and Financial SectorForeign Trade and International FinanceGovernment Operations and PoliticsHealthHousing and Community DevelopmentImmigrationInternational AffairsLabor and EmploymentLawNative AmericansPublic Lands and Natural ResourcesScience, Technology, CommunicationsSocial WelfareSports and RecreationTransportation and Public WorksWater Resources Development

Constitutional authority

The clause the sponsor cites as Congress’s power to enact H.R. 1414, as entered in the Congressional Record.

[Congressional Record Volume 171, Number 32 (Tuesday, February 18, 2025)][House]From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]By Mr. GOTTHEIMER:H.R. 1414.Congress has the power to enact this legislation pursuantto the following:Article I Section 8[Page H723]

Source: congress.gov · legiscan.com